{"title":"CAR - t细胞治疗后继发性t细胞恶性肿瘤的风险。","authors":"","doi":"10.1136/dtb.2025.000023","DOIUrl":null,"url":null,"abstract":"<p><p><b>Overview of:</b> European Medicines Agency. CAR T-cell medicines: PRAC identifies risk of secondary malignancies of T-cell origin [online], 2024. Available: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-june-2024[Accessed 22 May 2025].</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"148"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk of secondary T-cell malignancy after CAR T-cell therapy.\",\"authors\":\"\",\"doi\":\"10.1136/dtb.2025.000023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Overview of:</b> European Medicines Agency. CAR T-cell medicines: PRAC identifies risk of secondary malignancies of T-cell origin [online], 2024. Available: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-june-2024[Accessed 22 May 2025].</p>\",\"PeriodicalId\":11277,\"journal\":{\"name\":\"Drug and Therapeutics Bulletin\",\"volume\":\" \",\"pages\":\"148\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug and Therapeutics Bulletin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/dtb.2025.000023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug and Therapeutics Bulletin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/dtb.2025.000023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Risk of secondary T-cell malignancy after CAR T-cell therapy.
Overview of: European Medicines Agency. CAR T-cell medicines: PRAC identifies risk of secondary malignancies of T-cell origin [online], 2024. Available: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-june-2024[Accessed 22 May 2025].
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
